CClinicalTrials.gg
RecruitingNCT07356557OBSERVANCE MHMUpdated Jun 30, 2026

Evaluation of Therapeutic Adherence Among Patients Followed in the Department of Hereditary Metabolic Diseases at Necker Hospital

An observational study in Metabolic Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 7 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
7 Years to 20 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate treatment adherence among patients followed in the Department of Inherited Metabolic Diseases at Necker Hospital, in order to assess the need for implementing a therapeutic education workshop focused on medication adherence.

Read the detailed description

There is limited data in the literature regarding treatment adherence in children with metabolic disorders. A 2011 study on phenylketonuria highlighted a decline in dietary adherence during adolescence. Another study, dating from 1996 and focusing on urea cycle disorders, emphasized the importance of good treatment adherence for maintaining disease control. Furthermore, larger-scale research in epileptic patients has identified several barriers to treatment compliance, highlighting the crucial role of treatment adherence in improving disease control.

The purpose of this study is to evaluate treatment adherence among patients followed in the Department of Inherited Metabolic Diseases at Necker Hospital, in order to assess the need for implementing a therapeutic education workshop focused on medication adherence.

02

Conditions studied

  • Metabolic Diseases

Keywords

  • Metabolic disease
  • Daily oral drug treatment
  • Medication adherence
  • Therapeutic education workshop
03

Who can participate

Ages eligible
7 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients followed in the department of hereditary metabolic diseases at Necker Hospital, having specific oral drug treatment, and having a scheduled care appointment at Necker Hospital as part of their usual follow-up, during the study inclusion period.

Inclusion criteria

  • All patients followed in the Hereditary Metabolic Diseases department of Necker Hospital during their visit to the department for their usual care and having a specific daily oral medication treatment.
  • Children aged at least 7 years and adolescents/young adults
  • Holders of parental authority and children or adolescents or adults' patients informed and consenting to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Metabolic disease without oral medication (intravenous treatments, amino acid mixtures, and dietary regimens are not evaluated).
  • Patient and parents not proficient in French.
  • Refusal by the patient's holders of parental authority or adult patient to participate in the study and/or refusal of the child/adolescent.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Patients, children aged at least 7 years and adolescents/young adults followed in the pediatric department of hereditary metabolic diseases of Necker Hospital, having specific oral drug treatment.

    Other: Questionnaire · Other: Calculation of the metabolic balance score

Interventions

  • OtherQuestionnaire

    A pseudonymized questionnaire assessing treatment adherence, understanding of the illness, knowledge of medications, and the number of oral medications taken is given to patients and/or their parents during a follow-up visit, whether in a consultation, day hospital, or conventional hospitalization. It is completed by parents and children aged 7 and older, as well as by adolescents and young adults. The responses will not be disclosed to the physicians in the department.

  • OtherCalculation of the metabolic balance score

    For patients with urea cycle deficiency, a metabolic balance score will be calculated independently from retrospective data from the medical record, in the last two years preceding the completion of the questionnaire.

05

What researchers measure

Primary outcomes

  1. Assessment of therapeutic adherence

    Therapeutic adherence score, established from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

Secondary outcomes

  1. Number of treatments taken each day

    Quantification of the number of medications taken daily based on the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

  2. Knowledge of the disease

    Assessment of patients' and their parents' knowledge of the disease establish from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

  3. Knowledge of treatments

    Accordance of patients' and their parents' knowledge of treatments, based on the declarations of patients and their parents in the study questionnaire and the patient's prescriptions in the medical record.

    Time frame: Time 0

  4. Correlation between the therapeutic adherence score and the number of medications taken daily by patients

    The therapeutic adherence score and the number of medications taken daily are established from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

  5. Correlation between the therapeutic adherence score and the age of patients

    Therapeutic adherence score, established from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

  6. Correlation between the therapeutic adherence score and patients' and their parents' knowledge of the disease

    The therapeutic adherence score and the knowledge of the disease are established from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

  7. Correlation between the therapeutic adherence score and patients' and their parents' knowledge of treatments

    The therapeutic adherence score and the knowledge of treatments are established from the declarations of patients and their parents to the study questionnaire and on the patient's prescription.

    Time frame: Time 0

  8. Correlation between therapeutic adherence score and metabolic balance for patients cared for urea cycle deficiency

    For patients with urea cycle deficiency, a metabolic balance score will be calculated independently from retrospective data from the medical record, in the last two years preceding the completion of the questionnaire based on the following clinical data: * Number of ammonia levels \> 100 µmol/L, * Mean and median follow-up ammonia levels, * Number of glutamine levels \> 1000 µmol/L, * Number of hospitalizations for decompensation.

    Time frame: Time 0

  9. Assessment of medication adherence in the event of a travel

    Assessment of patients' and their parents' medication adherence in the event of a travel, established from the declarations of patients and their parents to the study questionnaire.

    Time frame: Time 0

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Modi AC, et al. "Adolescent adherence to antiepileptic drug therapy: determinants and clinical outcomes." JAMA, 2011.
  • Maestri NE, et al. "Outcome of urea cycle disorder patients: importance of metabolic control and compliance." Journal of Pediatrics, 1996.
  • Ten Hoedt AE, et al. "Adherence to treatment in phenylketonuria: challenges and improvements." Molecular Genetics and Metabolism, 2011.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07356557
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Feb 23, 2026
Primary completion
Feb 23, 2028 (estimated)
Completion
Feb 23, 2028 (estimated)
Last update
Jun 30, 2026

Study contacts

Margaux GASCHIGNARD, M.D.
Contact
margaux.gaschignard@aphp.fr
01 44 49 40 23 ext. +33
Hélène Morel
Contact
helene.morel@aphp.fr
01 71 19 63 46 ext. +33
Margaux MD GASCHIGNARD, M.D.
principal investigator · Assistance Publique - Hôpitaux de Paris
Pascale de LONLAY, M.D., PhD
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion